Henrique Tada of ALANAC, the association that brings together Brazil's domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories' internationalisation efforts, and the policy reforms he hopes that the country's new administration will roll out.
The pandemic has given us the opportunity to reclaim our spot in the APIs market and not repeat the mistakes of the past
Tags:
